Amphotericin B

Catalog No.S1636 Synonyms: NSC 527017

For research use only.

Amphotericin B (AMB, NSC 527017) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes.

Amphotericin B  Chemical Structure

CAS No. 1397-89-3

Selleck's Amphotericin B has been cited by 9 Publications

Purity & Quality Control

Choose Selective Antibiotics for Mammalian Cell Culture Inhibitors

Biological Activity

Description Amphotericin B (AMB, NSC 527017) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes.
ergosterol [1]
In vitro

Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. Amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. [1] Amphotericin B interacts with cholesterol, the major sterol of mammal membranes, thus limiting the usefulness of Amphotericin B due to its relatively high toxicity. Amphotericin B is dispersed as a pre-micellar or as a highly aggregated state in the subphase. [2] Amphotericin B only kills unicellular Leishmania promastigotes (LPs) when aqueous pores permeable to small cations and anions are formed. Amphotericin B (0.1 mM) induces a polarization potential, indicating K+ leakage in KCl-loaded liposomes suspended in an iso-osmotic sucrose solution. Amphotericin B (0.05 mM) exhibits a nearly total collapse of the negative membrane potential, indicating Na+ entry into the cells. [3]

In vivo Amphotericin B results in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. Amphotericin B markedly reduces PrPSc levels in mice with transmissible subacute spongiform encephalopathies (TSSE). [4] Amphotericin B exerts a direct effect on Plasmodium falciparum and influences eryptosis of infected erythrocytes, parasitemia and hostsurvival in murine malaria. Amphotericin B tends to delay the increase of parasitemia and significantly delays host death plasmodium berghei-infected mice. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 924.08


CAS No. 1397-89-3
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05108545 Not yet recruiting Drug: Amphotericin B liposomes Neutropenia and Fever CSPC ZhongQi Pharmaceutical Technology Co. Ltd. December 15 2021 Phase 3
NCT04993222 Completed Drug: Amphotericin B liposome for injection|Drug: AmBisome® Bioequivalence CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd. June 4 2020 Phase 1
NCT03905447 Terminated Drug: PC945|Drug: Standard of Care Aspergillosis|Lung Transplant Infection Pulmocide Ltd September 17 2019 Phase 2
NCT03828773 Recruiting Drug: Posaconazole|Drug: Fluconazole Candidiasis|Fungal Infection|Acute Myeloid Leukemia|Genetic Predisposition|Aspergillosis Bochud Pierre-Yves|Swiss National Science Foundation|Centre Hospitalier Universitaire Vaudois February 11 2019 Not Applicable
NCT03814343 Completed Drug: amphotericin B in 30% DMSO|Drug: 30% DMSO Fungal Infection|Onychomycosis|Fungus Nail Mahidol University January 15 2019 Phase 4
NCT03399955 Unknown status Drug: Paromomycin|Drug: Ambisome|Drug: Miltefosine PKDL - Post-Kala-Azar Dermal Leishmanioid Drugs for Neglected Diseases May 9 2018 Phase 2

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Amphotericin B | Amphotericin B ic50 | Amphotericin B price | Amphotericin B cost | Amphotericin B solubility dmso | Amphotericin B purchase | Amphotericin B manufacturer | Amphotericin B research buy | Amphotericin B order | Amphotericin B mouse | Amphotericin B chemical structure | Amphotericin B mw | Amphotericin B molecular weight | Amphotericin B datasheet | Amphotericin B supplier | Amphotericin B in vitro | Amphotericin B cell line | Amphotericin B concentration | Amphotericin B nmr